Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice

利用单细胞测序和人肝嵌合小鼠揭示间日疟原虫休眠子形成和发育的寄生虫和宿主决定因素

基本信息

  • 批准号:
    10452314
  • 负责人:
  • 金额:
    $ 94.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-07 至 2027-01-31
  • 项目状态:
    未结题

项目摘要

The human malaria-causing parasite Plasmodium vivax is geographically the most widespread of all the Plasmodium species. P. vivax is a major cause of morbidity in endemic regions of Asia, Oceania, Central and South America, as well as the horn of Africa. In these regions, P. vivax infections in pregnant women significantly contribute to early pregnancy loss, reduced birth weight and infant mortality. Notably, P. vivax is a major concern in an arena of malaria eradication due to its unique biology. Specifically, P. vivax sporozoite infectivity of hepatocytes does not always lead to the onset of schizogony and transition to blood stage disease, as is the case for P. falciparum. Rather, a sporozoite can enter a host hepatocyte, dedifferentiate and then lie dormant within the host hepatocyte for weeks, months or even years, before reactivating. This dormant or latent liver stage form is known as the hypnozoite and in continued efforts towards malaria elimination and eradication, the hypnozoite is a formidable foe. Indeed, the endemicity of P. vivax throughout tropical as well as temperate climate zones is attributed to the parasite’s ability to form hypnozoites, which after reactivating, case relapses of blood stage infection and concomitant transmission. Antimalarial drugs almost exclusively target the symptomatic blood stage of the life cycle and do not target the hypnozoite and thus treatment of P. vivax blood stage infections with standard drug regimens allows for further relapses and will not aid in disease eradication. Historically, the only approved drug active against P. vivax hypnozoites was primaquine although an improved 8-aminoquinoline drug, tafenoquine, has recently received approval for the treatment of relapsing malaria. Unfortunately, primaquine’s short half-life, long dosage regimen and incompatibility with glucose-6- phosphate dehydrogenase deficiency, prevent its use for mass elimination campaigns. Thus, there is a need for novel interventions that will negatively affect hypnozoite formation, survival and relapse. Thus, the research in this proposal aims to shed biological insight on the hypnozoite. This application aims to address three critical biological questions pertaining to P. vivax hypnozoite biology and answering these questions should aid in the discovery of novel interventions to prevent hypnozoite relapse and the continued spread of P. vivax disease. Specifically, are there intrinsic factors that are pre-programmed in the P. vivax sporozoite that determine its fate once it reaches the liver to become either a replicating schizont or a dormant hypnozoite? How does the dormant hypnozoite manipulate its host cell in order to maintain its long-term residency? Can we develop a model of hypnozoite relapse in order to gain insight into the triggers that promote hypnozoite reactivation? Using a human-liver chimeric mouse model alongside innovative methods of single cell isolation and transcriptional profiling, we hope to being to address these challenges.
引起人类疟疾的寄生虫间日疟原虫在地理上分布最广 疟原虫的种类间日疟原虫是亚洲,大洋洲, 中美洲和南美洲,以及非洲之角。在这些地区,妊娠妇女中的间日疟原虫感染 妇女在很大程度上造成早孕流产、出生体重下降和婴儿死亡。值得注意的是,P。 间日疟原虫由于其独特的生物学特性而成为疟疾根除竞技场中的主要关注点。间日疟原虫P. vivax 肝细胞的子孢子感染性并不总是导致胚胎生殖的开始和向血液的转化 阶段疾病,如恶性疟原虫的情况。相反,子孢子可以进入宿主肝细胞, 去分化,然后在宿主肝细胞内休眠数周、数月甚至数年, 重新激活这种休眠或潜伏的肝脏阶段形式被称为催眠子, 在消灭疟疾方面,催眠虫是一个可怕的敌人。事实上,P. 热带和温带气候区的间日疟原虫是由于寄生虫的能力, 催眠虫,其在重新激活后,引起血液期感染复发和伴随传播。 抗疟药物几乎只针对生命周期的症状性血液阶段,而不针对 催眠子以及因此用标准药物方案治疗间日疟原虫血液期感染允许 进一步复发,并且将无助于根除疾病。 从历史上看,唯一批准的抗间日疟原虫催眠虫的药物是伯氨喹, 一种改进的8-氨基喹啉药物,他非诺喹,最近已被批准用于治疗复发性 疟疾不幸的是,伯氨喹的半衰期短,剂量方案长,与葡萄糖-6- 磷酸脱氢酶缺乏症,防止其用于大规模消除运动。由此可见,有一 需要新的干预措施,将产生负面影响催眠虫的形成,生存和复发。因此 这项建议的研究目的是揭示催眠虫的生物学见解。本申请旨在解决 关于间日疟原虫催眠子生物学的三个关键生物学问题,并回答这些问题 应该有助于发现新的干预措施,以防止催眠虫复发和持续传播, P.间日疟原虫病 具体来说,间日疟原虫子孢子中是否存在预先编程的内在因子, 决定它到达肝脏后的命运,成为一个复制体或休眠的催眠体? 休眠的催眠子如何操纵宿主细胞以维持其长期居住?可以 我们开发了一个催眠子复发的模型,以深入了解促进催眠子复发的触发因素。 重新激活?使用人肝嵌合小鼠模型以及单细胞移植的创新方法 分离和转录谱分析,我们希望能够应对这些挑战。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ashley M Vaughan其他文献

Ashley M Vaughan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ashley M Vaughan', 18)}}的其他基金

Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice
利用单细胞测序和人肝嵌合小鼠揭示间日疟原虫休眠子形成和发育的寄生虫和宿主决定因素
  • 批准号:
    10565932
  • 财政年份:
    2022
  • 资助金额:
    $ 94.67万
  • 项目类别:
Mechanisms of nutrient acquisition by malaria parasite mosquito stages
疟疾寄生虫蚊子阶段获取营养的机制
  • 批准号:
    9806568
  • 财政年份:
    2019
  • 资助金额:
    $ 94.67万
  • 项目类别:
Experimental genetic crosses for malaria research
疟疾研究的实验性基因杂交
  • 批准号:
    9359277
  • 财政年份:
    2017
  • 资助金额:
    $ 94.67万
  • 项目类别:
Experimental genetic crosses for malaria research
疟疾研究的实验性基因杂交
  • 批准号:
    10216643
  • 财政年份:
    2017
  • 资助金额:
    $ 94.67万
  • 项目类别:
Experimental Plasmodium falciparum crosses using human-liver chimeric mice
使用人肝嵌合小鼠进行实验性恶性疟原虫杂交
  • 批准号:
    8959920
  • 财政年份:
    2014
  • 资助金额:
    $ 94.67万
  • 项目类别:
Experimental genetic crosses for malaria research
疟疾研究的实验性基因杂交
  • 批准号:
    9751189
  • 财政年份:
  • 资助金额:
    $ 94.67万
  • 项目类别:

相似海外基金

Multi-component interventions to reducing unhealthy diets and physical inactivity among adolescents and youth in sub-Saharan Africa (Generation H)
采取多方干预措施减少撒哈拉以南非洲青少年的不健康饮食和缺乏身体活动(H 代)
  • 批准号:
    10106976
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    EU-Funded
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Fellowship
Decolonization, Appropriation and the Materials of Literature in Africa and its Diaspora
非洲及其侨民的非殖民化、挪用和文学材料
  • 批准号:
    EP/Y024516/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Research Grant
Exploring "Actionable Information" for Learning Improvement in Rural East Africa: A Positive Deviance Approach
探索东非农村地区学习改进的“可行信息”:积极偏差方法
  • 批准号:
    24K00390
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Water stressed cities: individual choice, access to water and pathways to resilience in sub-Saharan Africa
缺水城市:撒哈拉以南非洲地区的个人选择、水资源获取和恢复力途径
  • 批准号:
    MR/X022943/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Fellowship
Protecting Women from Economic shocks to fight HIV in Africa (POWER)
保护非洲妇女免受经济冲击,抗击艾滋病毒 (POWER)
  • 批准号:
    MR/Y003837/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Fellowship
Tackling antimicrobial resistance across dentistry in Sub-Saharan Africa.
解决撒哈拉以南非洲牙科领域的抗菌素耐药性问题。
  • 批准号:
    MR/Y019695/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Research Grant
ePowerCart - Affordable Mobile Clean Energy for Remote Communities in Rural Sub-Saharan Africa and India
ePowerCart - 为撒哈拉以南非洲和印度农村偏远社区提供经济实惠的移动清洁能源
  • 批准号:
    10076185
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Collaborative R&D
The Open fracture National Evaluation (ONE) Study - South Africa: Improving outcomes in the care of open fractures in low resource settings
开放性骨折国家评估 (ONE) 研究 - 南非:改善资源匮乏地区开放性骨折的护理效果
  • 批准号:
    MR/Y00955X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Fellowship
Recognising & supporting informal mhealth in Africa through grassroots interventions (REIMAGINE)
认识
  • 批准号:
    MR/Y015614/1
  • 财政年份:
    2024
  • 资助金额:
    $ 94.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了